COVID-19 and Influenza Coadministered Vaccines May Loiwer Risk of MACE in Older Adults

According to a recent study, coadministration of the COVID-19 vaccine with the annual influenza vaccine may reduce COVID-19-related major adverse cardiovascular events (MACE) among older adults, especially those with comorbidities.

In the study, researchers conducted a target trial emulation using electronic health record data of more than one million veterans (mean age, 70 years; 92 percent men) who received same-day coadministration of COVID-19 and influenza vaccines and compared outcomes with individuals who received the influenza vaccine alone over a median follow-up of 8 months. The main outcome of interest was a composite endpoint of COVID-19-associated MACE, including COVID-19-associated cardiovascular (CV) death, myocardial infarction (MI), stroke or heart failure (HF) hospitalization.

The 2024-2025 COVID-19 vaccines included those manufactured by Moderna, Novavax and Pfizer-BioNTech and the 2024-2025 seasonal influenza vaccines included those manufactured by AstraZeneca, GlaxoSmithKline, Sanofi and Seqirus.

According to the researchers, COVID-19 vaccination was associated with lower risk for COVID-19-associated MACE vs. no COVID-19 vaccination (risk difference, two per 10,000 population), but was only statistically significant among people aged 75 years or older, a group that also experienced the largest absolute risk reduction (risk difference, 5.5 per 10,000 population).

Among the individual components of the main composite endpoint, COVID-19 vaccination was associated with lower risk for COVID-19-associated CV death (risk difference, one per 10,000 population, MI (risk difference, 0.8 per 10,000 population) and HF hospitalization (risk difference, 0.8 per 10,000 population) but not COVID-19-associated stroke (risk difference, 0.4 per 10,000 population).

The researchers reported COVID-19-associated MACE risk reductions were consistent across subgroups; however, people with comorbidities appeared to derive more benefit from COVID-19 vaccination.

References

Buzby, S. Coadministration of COVID-19, Influenza Vaccines May Lower MACE Risk in Older Adults. Healio, June 19, 2026. Accessed at www.healio.com/news/cardiology/20260619/coadministration-of-covid19-influenza-vaccines-may-lower-mace-risk-in-older-adults.

BSTQ Staff
BioSupply Trends Quarterly [BSTQ] is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace. With timely and critical information, each themed issue covers topics ranging from product breakthroughs, industry insights and innovations, up-to-the-minute news on the latest clinical trials, accessibility, and service and safety concerns.